Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: Major roles for CYP2J2 and CYP3A

Drug Metabolism and Disposition

Volumn 34, Issue 11, 2006, Pages 1793-1797

  Liu, Kwang Hyeon ^a,c   Kim, Mi Gyung ^a   Lee, Dong Jun ^a   Yoon, Yune Jung ^a   Kim, Min Jung ^a   Shon, Ji Hong ^a   Chang, Soo Choi ^b   Young, Kil Choi ^b   Desta, Zeuresenay ^d   Shin, Jae Gook ^a,e  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Inje University   (South Korea)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Pharmacology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CAREBASTINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DESALKYLEBASTINE; DRUG METABOLITE; EBASTINE; HYDROXYEBASTINE; KETOCONAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME MECHANISM; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BUTYROPHENONES; CYTOCHROME P-450 ENZYME SYSTEM; HISTAMINE H1 ANTAGONISTS; HUMANS; MICROSOMES, LIVER; OXYGENASES; PIPERIDINES;

EID: 33751112296     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010488     Document Type: Article

References (17)

1. Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, and Roberts DJ (2005) Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol 59:346-354.
2. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
3. Hashizume T, Mise M, Matsumoto S, Terauchi Y, Fujii T, Imaoka S, Funae Y, Kamataki T, and Miyazaki H (2001) A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 29:798-805.
4. Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, and Inaba T (1998) N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 26:566-571.
5. Kang W, Liu KH, Ryu JY, and Shin JG (2004) Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 813:75-80.
6. Lasseter KC, Dilzer SC, Vargas R, Waldman S, and Noveck RJ (2004) Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet 43:121-129.
7. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, and Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631-636.
8. Llupia J, Gras J, and Llenas J (2003) Comparative antiallergic effects of second-generation H1-antihistamines ebastine, cetirizine and loratadine in preclinical models. Arzneim-Forsch 53:93-97.
9. Matsumoto S, Hirama T, Kim HJ, Nagata K, and Yamazoe Y (2003) In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33:615-623.
10. Parikh S, Gagne P, Miller V, Crespi C, Thummel K, and Patten C (2003) CYP2J2 and CYP4F12 are active for the metabolism of non-sedating antihistamines: terfenadine and astemizole. Drug Metab Rev 35:190.
11. Rohatagi S, Gillen M, Aubeneau M, Jan C, Pandit B, Jensen BK, and Rhodes G (2001) Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. Int J Clin Pharmacol Ther 39:126-134.
12. Schrag ML and Wienkers LC (2001) Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Adv Exp Med Biol 500:347-350.
13. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, and Flockhart DA (2002) Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 30:1102-1107.
14. Shin JG, Soukhova N, and Flockhart DA (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078-1084.
15. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
16. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
17. Yamaguchi T, Hashizume T, Matsuda M, Sakashita M, Fujii T, Sekine Y, Nakashima M, and Uematsu T (1994) Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneim-Forsch 44:59-64.